SUNPHARMA

Mon, 12 Oct, 2026

• Filing

  Director resignation filed

  NSE ↗
• Filing

  Resignation of Director/KMP/SMP filing submitted

  NSE ↗
• Filing

  Director resignation announced, board meeting outcome filed on 12 October 2026

  BSE ↗

Wed, 7 Oct, 2026

• FilingBoard meeting called on 12 Oct 2026 to consider and approve issuance of listed, rated, unsecured, redeemable, non-conve…BSE ↗

Mon, 28 Sept, 2026

• Filing

  Sun Pharmaceutical informs exchange of press release regarding Lerodalcibep licensing agreement

  NSE ↗

Wed, 9 Sept, 2026

• Filing

  Sun Pharmaceutical incorporated a subsidiary company

  NSE ↗

Mon, 17 Aug, 2026

• Filing

  Update filed on Lipitor antitrust litigation with no disclosed outcome, settlement, or financial impact

  BSE ↗

Thu, 6 Aug, 2026

• Filing

  Receipt of no-objection letters from stock exchanges for reclassification of promoter group

  NSE ↗

Wed, 5 Aug, 2026

• Filing

  Credit rating update filed under Regulation 30

  BSE ↗

Fri, 31 Jul, 2026

• FilingQ1 FY2026-27 unaudited financial results filed following board meetingNSE ↗
• Filing

  Outcome of 34th Annual General Meeting held on 31 July 2026 filed

  BSE ↗
• Filing

  Q1 FY2026-27 unaudited standalone and consolidated financial results filed

  BSE ↗

Wed, 29 Jul, 2026

• Filing

  Sun Pharma receives approval to manufacture and market semaglutide in Brazil

  NSE ↗
• Filing

  Sun Pharma receives regulatory approval to manufacture and market semaglutide in Brazil

  BSE ↗

Fri, 24 Jul, 2026

• FilingSun Pharma's proposed acquisition of Organon received shareholder approval, aNSE ↗
• Filing

  Sun Pharma notes Organon shareholder approval for proposed acquisition

  BSE ↗